Clinical Trials Logo

Clinical Trial Summary

national and multi-center trial for medical therapy of chronic radiation proctitis inducing anorectal bleedings


Clinical Trial Description

Radiation proctitis is an inflammation of rectal mucosa, a complication following radiation therapy for cancers of the prostate, cervix, uterus, bladder and other malignancies in the pelvic area. Around 20 % of radiation patients develop radiation proctitis. There is a significant lack of trial treatments for radiation proctitis, even more, the studies often are small and single center designed or case series. In 2 recent reviews pointing out the management of radiation proctitis (2018 and 2016) a summary of current options in therapy according to current scientific knowledge is given. Unfortunately, these studies are about interventional options with the serious risk of complication. Only little data and lack of significance in smaller series on conservative strategies are given. The goal of the trial is to implement a specific medication in the management and every grade of radiation proctitis - concomitant to eventual need of MMPF is described with potent anti-inflammatory mucosal capacity reducing bleeding, pain and urgency symptoms in patients with hemorrhoidal and/or postoperative symptoms. By using a placebo instead of comparative oral medications (with low evidence) this study might illustrate clinical significance of expected results as well as information on the natural history of radiation proctitis. The goal of the study is to compare the number of necessary interventions required to stop bleeding in chronic radiation proctitis in patients receiving MMPF in comparison to patients in the control group receiving Placebo within 12 months of medical treatment. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04335617
Study type Interventional
Source Medical University Innsbruck
Contact Irmgard Kronberger, MD
Phone +43 512 504
Email irmgard.kronberger@i-med.ac.at
Status Recruiting
Phase Phase 3
Start date February 26, 2020
Completion date August 26, 2023